Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention
BACKGROUND: The TARGET study has been criticised for sub-optimal platelet inhibition with tirofiban. We aimed to compare a high-dose bolus regimen of tirofiban (hd-tirofiban) to standard dose of abciximab for patients undergoing percutaneous coronary intervention (PCI).
METHODS: We assessed consecutive patients who received either hd-tirofiban (25 mcg/kg bolus followed by 0.15 mcg/kg/min infusion for 18 h) or standard dose abciximab. In-hospital and 6-month outcomes were obtained in all cases.
RESULTS: Over an 18-month period, 109 patients who received hd-tirofiban were compared with 110 patients who received abciximab. Both hd-tirofiban and abciximab groups had acute coronary syndromes in 86% and 80% and diabetes in 10% and 13% respectively. Most patients had coronary stent implantation (96% vs. 98%). Thrombocytopenia (platelet count< 100,000) developed in 0.9% of patients receiving hd-tirofiban and 2% of patients receiving abciximab (p = 0.566). Bleeding requiring transfusion occurred in 7.3% and 3% of patients respectively (p = 0.118). Peri-procedural troponin rise was 0.9% in patients receiving hd-tirofiban and 5.5% in patients receiving abciximab (p = 0.07). MACE (Myocardial infarction, Stroke, Revascularisation and Death) at 6 months was 23% in the hd-tirofiban group and 20% in the abciximab group (p = 0.711). The pharmaceutical costs were AUD 322 for hd-tirofiban (one ampoule) and AUD 1,350 for abciximab (3 ampoules).
CONCLUSION: There was a small increase in bleeding requiring transfusion and a lower rate of peri-procedural troponin rise in the hd-tirofiban group however, the overall 6-month MACE rates were similar in both groups. There was a considerable cost-saving with the use of hd-tirofiban. A prospective randomised trial of hd-tirofiban vs. abciximab is warranted.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2006 |
---|---|
Erschienen: |
2006 |
Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
---|---|
Enthalten in: |
International journal of cardiology - 109(2006), 1 vom: 28. Apr., Seite 16-20 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gunasekara, Athula P [VerfasserIn] |
---|
Anmerkungen: |
Date Completed 27.09.2006 Date Revised 01.12.2018 published: Print-Electronic Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM156513234 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM156513234 | ||
003 | DE-627 | ||
005 | 20231223074317.0 | ||
007 | tu | ||
008 | 231223s2006 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0522.xml |
035 | |a (DE-627)NLM156513234 | ||
035 | |a (NLM)16014315 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Gunasekara, Athula P |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention |
264 | 1 | |c 2006 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 27.09.2006 | ||
500 | |a Date Revised 01.12.2018 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: The TARGET study has been criticised for sub-optimal platelet inhibition with tirofiban. We aimed to compare a high-dose bolus regimen of tirofiban (hd-tirofiban) to standard dose of abciximab for patients undergoing percutaneous coronary intervention (PCI) | ||
520 | |a METHODS: We assessed consecutive patients who received either hd-tirofiban (25 mcg/kg bolus followed by 0.15 mcg/kg/min infusion for 18 h) or standard dose abciximab. In-hospital and 6-month outcomes were obtained in all cases | ||
520 | |a RESULTS: Over an 18-month period, 109 patients who received hd-tirofiban were compared with 110 patients who received abciximab. Both hd-tirofiban and abciximab groups had acute coronary syndromes in 86% and 80% and diabetes in 10% and 13% respectively. Most patients had coronary stent implantation (96% vs. 98%). Thrombocytopenia (platelet count< 100,000) developed in 0.9% of patients receiving hd-tirofiban and 2% of patients receiving abciximab (p = 0.566). Bleeding requiring transfusion occurred in 7.3% and 3% of patients respectively (p = 0.118). Peri-procedural troponin rise was 0.9% in patients receiving hd-tirofiban and 5.5% in patients receiving abciximab (p = 0.07). MACE (Myocardial infarction, Stroke, Revascularisation and Death) at 6 months was 23% in the hd-tirofiban group and 20% in the abciximab group (p = 0.711). The pharmaceutical costs were AUD 322 for hd-tirofiban (one ampoule) and AUD 1,350 for abciximab (3 ampoules) | ||
520 | |a CONCLUSION: There was a small increase in bleeding requiring transfusion and a lower rate of peri-procedural troponin rise in the hd-tirofiban group however, the overall 6-month MACE rates were similar in both groups. There was a considerable cost-saving with the use of hd-tirofiban. A prospective randomised trial of hd-tirofiban vs. abciximab is warranted | ||
650 | 4 | |a Comparative Study | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Immunoglobulin Fab Fragments |2 NLM | |
650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
650 | 7 | |a Platelet Glycoprotein GPIIb-IIIa Complex |2 NLM | |
650 | 7 | |a Troponin |2 NLM | |
650 | 7 | |a Tyrosine |2 NLM | |
650 | 7 | |a 42HK56048U |2 NLM | |
650 | 7 | |a Tirofiban |2 NLM | |
650 | 7 | |a GGX234SI5H |2 NLM | |
650 | 7 | |a Abciximab |2 NLM | |
650 | 7 | |a X85G7936GV |2 NLM | |
700 | 1 | |a Walters, Darren L |e verfasserin |4 aut | |
700 | 1 | |a Aroney, Con N |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of cardiology |d 1984 |g 109(2006), 1 vom: 28. Apr., Seite 16-20 |w (DE-627)NLM012621196 |x 1874-1754 |7 nnns |
773 | 1 | 8 | |g volume:109 |g year:2006 |g number:1 |g day:28 |g month:04 |g pages:16-20 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 109 |j 2006 |e 1 |b 28 |c 04 |h 16-20 |